THURSDAY | SEPTEMBER 24, 2020
|
|
View On-Demand Recordings of ASIPP Virtual Annual Meeting Now!
Did you pre-register for the ASIPP Virtual Annual Meeting? You may now view recordings of all sessions for free through October 5. Click here to enter the portal login and use the login credentials you used for the live meeting.
You will find the recordings by clicking the “On Demand” menu tab. If you have questions about your login credentials, contact Karen Avery at kavery@asipp.org.
ASIPP will offer reduced-fee pricing for access to the meeting recordings after October 5. Fee-based on-demand registrants will have access to the recordings and exhibit hall through June 2021. Watch for additional information next week!
|
|
Get up to date on the 2021
Coding Changes
|
|
Order Now - Recorded Virtual Review Courses
The following courses are offered:
- Documentation, Coding, Compliance, and Practice Management Review Course
- Controlled Substance Management Review Course
- Pain Medicine and Interventional Pain Management Comprehensive Review Course
|
|
ABIPP Recognizes Your Knowledge and Expertise
The American Board of Interventional Pain Physicians (ABIPP) has developed certification programs that recognize accepted levels of knowledge and expertise in the interventional pain management profession, with the goal of improved patient care. Hundreds of qualified physicians have made the commitment to become ABIPP certified.
ABIPP now offers the only competency
certification program for regenerative medicine.
For complete information about the examination requirements and to obtain an application packet, visit www.abipp.org or call 270-554-9412 x4217 or by email at summer@asipp.org.
|
|
TESTS OFFERED
ABIPP Part I - Theoretical written exam - TBD
ABIPP Part II - Oral and Hands-on practical exam - TBD
ABIPP Competency Exam - includes written, oral, and hands-on practical examinations TBD
Combined CSM/CCPM Exam for ABIPP Path – TBD
Competency Exam in Controlled Substance Management – TBD
Competency Exam in Coding, Compliance, and Practice Management - TBD
Regenerative Medicine Competency Exam - includes written, oral, and hands-on practical examinations – TBD
|
|
|
Blog:The Supreme Court Will Not Wreck Obamacare
Now that it appears certain that the Republicans will approve a new Supreme Court justice in the coming weeks, there is great concern among Obamacare supporters that this could well mean the end of Obamacare.
That concern is being amplified in the hyper partisan environment in the ramp-up to the election––it makes for good scare tactics.
The Obamacare case currently before the court deals with the 2017 repeal of the law's individual mandate for people to buy health insurance coverage. In 2012, Chief Justice John Roberts cast the deciding vote in the 5-4 decision upholding Obamacare generally, and the individual mandate specifically, as valid under the Congress' taxing power. After the mandate repeal in 2017, a number of Republican state attorneys general sued, arguing that since the mandate was no longer tied to a specific tax penalty, it had lost its legal underpinning. They also argued that because the individual mandate was key to a number of the law's provisions that made it a workable system of insurance, the entire law should fall, including preexisting conditions protections.
|
|
How Independent Practices Can Come Out of COVID-19 Stronger
The economic fallout of COVID-19 may accelerate acquisitions of independent practices unless practice leaders consider new, but not necessarily novel, ways of doing business.
September 21, 2020 - COVID-19 seems like the final nail in the coffin for independent practices. Devastating financial losses from the start of the pandemic, stagnating patient volumes, and a new appetite for virtual care is making it more difficult for independent practices, to put it frankly, remain independent.
“The jury is out, but COVID is probably going to exacerbate larger systems buying up independent practices because a lot of folks just aren’t going to be able to weather the storm long enough,” says Ryan Schmid, MBA, president and CEO of Vera Whole Health.
It is, however, important to note that by independent practices Schmid is talking about the traditional physician practice built on fee-for-service.
Vera Whole Health is not one of those traditional practices. Instead, the organization leverages value-based contracts to implement an advanced primary care model, and because of this business model, it did not experience the same revenue losses as traditional practices at the start of the pandemic.
|
|
Verma confirms Medicare loan recoupment delay amid Hill negotiations
CMS Administrator Seema Verma on Friday confirmed the agency is holding off on garnishing providers' Medicare payments amid congressional negotiations on repayment terms for the program's COVID-19 loans.
The Coronavirus Aid, Relief, and Economic Security Act expanded the Medicare Accelerated and Advance Payment Program in the spring and required CMS to begin garnishing 100% of loan recipients' Medicare payments starting four months after the loans were issued. The first loans went out in April, and recoupment should have started in August. But Modern Healthcare previously reported that CMS had not started withholding payments.
|
|
'You Need a Test': CDC Reverses Guidance for Asymptomatic COVID Contacts
— Fallout of political interference in the CDC continues
Asymptomatic people who have been exposed to COVID-19 should be tested, the CDC said on Friday, in a reversal of controversial guidance the agency introduced in late August.
It is now unequivocal, with the agency stating that for individuals without symptoms who have been in close contact with an infected person for at least 15 minutes: "You need a test."
The Infectious Diseases Society of America (IDSA) applauded Friday's reversal. Its president, Thomas File, MD, said in an emailed statement, "The return to a science-based approach to testing guidance from the Centers for Disease Control and Prevention is good news for public health and for our united fight against this pandemic."
|
|
Early Data Suggest Antibody Therapy May Cut COVID-19 Hospitalizations
Proof of concept data were announced from an interim analysis of a phase 2 trial evaluating the efficacy and safety of LY-CoV555 for the treatment of symptomatic mild to moderate coronavirus disease 2019 (COVID-19) in the outpatient setting.
LY-CoV555 is a potent neutralizing IgG1 monoclonal antibody directed against the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The investigational therapy is expected to block viral attachment and entry into human cells.
The ongoing randomized, double-blind, placebo-controlled BLAZE-1 trial is assessing the treatment in adult patients with mild to moderate COVID-19 symptoms who are not currently hospitalized. Patients were randomized to receive LY-CoV555 700mg, 2800mg, 7000mg, or placebo intravenously. The prespecified primary end point was the change from baseline to day 11 in SARS-CoV-2 viral load; additional end points included the proportion of patients who experienced COVID-19 hospitalization, ER visit or death from baseline to day 29.
|
|
HHS Outlines COVID Vax Distribution Strategy
— Sets January target, promises shipments the day after FDA gives its assent
The Health and Human Services (HHS) department on Wednesday unveiled general outlines for how the first COVID-19 vaccine doses will be shipped and administered.
Developed with the Department of Defense (DOD), the four-part strategy addresses engagement with state and local partners and other stakeholders; distribution under a "phased allocation methodology" still to be developed; safe vaccine administration and availability of auxiliary supplies; and data gathering via information technology to track distribution and administration.
|
|
Four Studies Indicate Benefits of Steroids for COVID-19
HealthDay News – Steroids can improve survival in patients with COVID-19, according to 3 randomized trials and a meta-analysis published online September 2 in the Journal of the American Medical Association.
Bruno M. Tomazini, MD, from Hospital Sírio-Linbanês in São Paulo, Brazil, and colleagues randomly assigned patients with COVID-19 and moderate-to-severe acute respiratory distress syndrome to either dexamethasone plus standard care (151 patients) or standard care alone (148 patients). The researchers found that patients randomly assigned to dexamethasone versus standard care had a mean of 6.6 vs 4.0 ventilator-free days. In a second study, Jonathan A.C. Sterne, PhD, from the University of Bristol in the United Kingdom, and colleagues estimated the association between corticosteroid administration versus usual care or placebo and 28-day all-cause mortality in a prospective meta-analysis involving 1,703 critically ill patients with COVID-19. The researchers found 222 deaths among 678 patients randomly assigned to corticosteroids and 425 deaths among 1025 patients randomly assigned to usual care or placebo (summary odds ratio, 0.66 based on a fixed-effect meta-analysis).
|
|
ASIPP® Partners with Fedora Billing And Revenue Cycle Management Company
ASIPP is now able to offer unique benefits for revenue cycle management with billing, etc.
Fedora is a company known to many of our board members and others. ASIPP® has reached an agreement with Fedora to provide exclusive discounts on billing or revenue cycle management that will decrease practice costs and promote growth, or at least stop deterioration. It is not just a billing company; they streamline the billing and receivable process and constantly update payor regulations keeping your practice up to on date on a daily basis.
Some of the ASIPP® Billing Program highlights are below:
Up to 50% savings for ASIPP® members for their billing or revenue cycle management for their offices and surgery centers:
- Expertise in interventional pain management billing for all types of services
- 99% Clearing House Rate
- 95% First-Time Claim Passage
- 23.4 Average Days in A/R
- Eligibility and Benefits Verification
- Pre-Certification/Prior Authorization
- Denials and A/R Management
|
|
Join The Group Purchasing
Organization Today
|
|
ASIPP® has formed a partnership with Henry Schein and PedsPal, a national GPO that has a successful history of negotiating better prices on medical supplies and creating value added services for the independent physician. Working with MedAssets, PedsPal provides excellent pricing on products like contrast media that alleviate some of the financial pressures you experience today. While the cost of contrast media has skyrocketed due to the single dose vial issue, because we have partnered with Henry Schein, this could enable you to purchase Omnipaque 240mg/50mL for slightly above $4.50.
Click on “view our discounted supplier prices” (Username: ASIPPmember and Password: Save) or click on the words "join for free now" and begin saving today!
|
|
Essentials of Regenerative Medicine in Interventional
Pain Management
|
|
|
|
Essentials of Regenerative Medicine in Interventional Pain Management is a book to bring concise, collective, and comprehensive information to interventional pain physicians practicing regenerative medicine in managing chronic pain. Regenerative medicine is an integral part of interventional pain management within the definitions of interventional pain management and interventional techniques.
Each chapter contains an introduction of the subject, historical context,pathophysiology, applicability of regenerative medicine with its evidence base, indications, anatomy, technical aspects, complications, and precautions for each topic when available and applicable. This comprehensive book consists of 35 chapters, more than 350 figures, and 50 tables.
|
|
| ORDER | Essentials of Regenerative Medicine in IPM
|
|
Control Your Waiting Room TV
Customized waiting room TV exclusively for ASIPP® members. Create your own ad-free television broadcasts using our videos, custom informational slides and your own YouTube videos. Even add local weather reports, news and live messages.
|
|
|
In addition, PainExam has now collaborated with ASIPP and offer 2 new programs:
|
|
|
|
|
2020 12th Annual Scientific
Meeting
|
|
|
|
|
|
|
|
|
|
